Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene)
1479-0001
Phase 1 other active
Quick answer
Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene) for Solid tumours with HER2 aberrations, Non-small cell lung cancer is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Solid tumours with HER2 aberrations, Non-small cell lung cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active